Bioavailability study of a new amoxicillin tablet designed for several modes of oral administration.

A new tablet of amoxicillin (Flemoxin solutab) has been formulated with galenic properties which allow it to be taken as a tablet, either swallowed, chewed or sucked, or to be taken after dispersion in water. This study was undertaken to compare the bioavailability of the new tablet (swallowed as such, or after dispersion) with a commercially available amoxicillin capsule and, for purposes of internal reference, with a Flemoxin forte suspension. Each formulation was administered to 12 volunteers according to a repeated 4 X 4 latin square design.

Bioavailability of new formulations of amoxicillin in relation to its absorption kinetics.

The newly developed amoxicillin (Flemoxin) formulations, a film-coated tablet (A) and an effervescent tablet (B) were tested for bioavailability against a commercial reference formulation (C). The content of amoxicillin in each formulation was 1000 mg. The cross-over study involved 12 healthy volunteers.

Interaction between substituted 1-[2-(diphenylmethoxy)ethyl] piperazines and dopamine receptors.

Substituted 1-[2-(diphenylmethoxy)ethyl]piperazines were tested for their affinity to specific [3H]dopamine binding sites in membrane preparations from the corpus striatum of the rat. In particular, 4-(3-phenyl-2-prop(en)yl)- and 4-(3-phenyl-2-butyl)-substitution yielded compounds potent in displacing [3H]dopamine from its binding sites, with IC50-values in the order of 10 nM. There was a significant correlation between the IC50-values determined in this binding assay and the IC50-values obtained for the same compounds in a previous study on their potency to inhibit the uptake of dopamine in synaptosomal preparations of the striatum of the rat.